60 patents
Utility
Acylated GLP-1/GLP-2 Dual Agonists
5 Jan 23
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided.
Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
Filed: 7 Jun 22
Utility
Fluid Delivery and Measurement Systems and Methods
6 Oct 22
Embodiments of this invention relate to a fluid delivery device.
Robert R. Gonnelli, Steven F. Levesque, David Lipson, Peter F. Marshall
Filed: 16 Jun 22
Utility
Adapter for a Fluid Transfer Device
22 Sep 22
An adapter (650) for transferring fluid between a first device (100) and a second device (800).
Christopher GREGORY, Michael BARENBOYM
Filed: 5 Aug 20
Utility
Formulations of GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) Analogues
25 Aug 22
Liquid formulations of GLP-2 analogues that make them suitable for long term storage as liquids and/or that makes them especially suitable for delivery by a drug delivery device are described.
Lise GIEHM, Claes MELANDER, Eva Horn MØLLER
Filed: 27 Sep 19
Utility
KV1.3 Blockers
11 Aug 22
The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.
Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen
Filed: 24 Feb 22
Utility
Pharmaceutical Composition for Subcutaneous Administration
4 Aug 22
This application concerns pharmaceutical compositions comprising cannabinoids which are suitable for subcutaneous administration in human subjects.
Erick Lucera, Jessica Barnes, Joseph Saldanha
Filed: 15 Jul 20
Utility
Acylated GLP-1/GLP-2 dual agonists
26 Jul 22
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided.
Bjarne Due Larsen, Jonathan Griffin, Lise Giehm, Alistair Vincent Gordon Edwards
Filed: 6 Apr 20
Utility
Amylin analogues
12 Jul 22
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes.
Jesper Mosolff Mathiesen, Jesper Skodborg Villadsen, Lise Giehm, Henrik Kofoed Munch, Dieter Wolfgang Hamprecht, Alexander Heim-Riether, Giacomo Fossati
Filed: 25 Oct 19
Utility
Pharmaceutical Parenteral Composition of Dual GLP1/2 Agonist
30 Jun 22
The present invention relates to pharmaceutical compositions suitable for parenteral administration in human subjects.
Lise Giehm, Alistair Vincent Gordon Edwards
Filed: 12 Jun 20
Design
Medicament delivery device
21 Jun 22
Christopher Gregory, Geoffrey Jenkins, Matthew Johnson
Filed: 1 Jul 20
Utility
Time Delay Mechanism for a Hydraulic Drug Delivery Device
26 May 22
A medicament delivery device may comprise a medicament chamber configured to hold a medicament, a plunger configured to move relative to the medicament chamber to expel the medicament from the medicament chamber, a pin configured to move from a first pin position wherein the pin prevents movement of the plunger to a second pin position wherein the pin allows movement of the plunger, an actuation assembly configured to move the pin from the first pin position to the second pin position, and a needle coupled to the medicament chamber.
Christopher Gregory, Geoffrey Jenkins
Filed: 11 Feb 22
Utility
Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
10 May 22
The use of gap junction intercellular communication (GJIC) modulators in the treatment or prevention of diabetic eye disease is disclosed, and more particularly to their use for the treatment or prevention of early stage diabetic retinopathy and diabetic macular edema by inhibiting apoptosis of retinal endothelial cells and inhibiting pericyte loss.
Bjarne Due Larsen, Ulrik Mouritzen, Dongjoon Kim, Sayon Roy
Filed: 4 May 18
Utility
KV1.3 blockers
5 Apr 22
The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.
Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen
Filed: 23 Jun 21
Utility
Homodetic cyclic peptides targeting alpha-4-beta-7 integrin
29 Mar 22
There is described herein antagonists of α4β7 integrin, and more particularly cyclic peptide antagonists, such as compounds of formula (I).
Manuel Perez Vazquez, M. Monzur Morshed, Adam Paul Kafal, Jennifer L. Hickey, Andrew Roughton
Filed: 10 May 18
Utility
Time delay mechanism for a hydraulic drug delivery device
22 Mar 22
A medicament delivery device may comprise a medicament chamber configured to hold a medicament, a plunger configured to move relative to the medicament chamber to expel the medicament from the medicament chamber, a pin configured to move from a first pin position wherein the pin prevents movement of the plunger to a second pin position wherein the pin allows movement of the plunger, an actuation assembly configured to move the pin from the first pin position to the second pin position, and a needle coupled to the medicament chamber.
Christopher Gregory, Geoffrey Jenkins
Filed: 20 Jun 18
Utility
Acylated glucagon analogue
15 Mar 22
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders.
Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Leo Thomas
Filed: 13 May 19
Utility
Acylated Glucagon Analogues
10 Mar 22
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders.
Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
Filed: 7 Jul 21
Utility
Gip Agonist Compounds and Methods
10 Feb 22
The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
Anne Pernille Tofteng SHELTON, Pia NØRREGAARD, Maria Alexandrovna DERYABINA, Bjarne Due LARSEN, Jacob Ulrik FOG
Filed: 2 Apr 21
Utility
Formulations of GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) Analogues
3 Feb 22
Liquid formulations of GLP-2 analogues are described that make it possible to include a preservative while allowing the formulation to be stabilised for long term storage as liquids and/or as multi-dose liquid formulations.
Henrik Rajesh Kumar PARSHAD, Lise GIEHM, Claes MELANDER
Filed: 27 Sep 19
Utility
Multi-Cartridge Fluid Delivery Device
20 Jan 22
A fluid delivery device for administering a first medicament and a second medicament includes a first fluid reservoir configured to contain the first medicament and a second fluid reservoir configured to contain the second medicament.
Robert R. GONNELLI, Steven F. LEVESQUE, Ronald V. NARDI
Filed: 1 Oct 21